Inhibition of Glycogenolysis in Primary Rat Hepatocytes by 1, 4-dideoxy-1,4-imino-D-arabinitol

Overview

Journal Biochem J

Specialty Biochemistry

Date 1999 Sep 8

PMID 10477265

Citations 18

Authors

B Andersen

A Rassov

N Westergaard

K Lundgren

Affiliations

Soon will be listed here.

Abstract

1,4-Dideoxy-1,4-imino-d-arabinitol (DAB) was identified previously as a potent inhibitor of both the phosphorylated and non-phosphorylated forms of glycogen phosphorylase (EC 2.4.1.1). In the present study, the effects of DAB were investigated in primary cultured rat hepatocytes. The transport of DAB into hepatocytes was dependent on time and DAB concentration. The rate of DAB transport was 192 pmol/min per mg of protein per mM DAB(medium-concentration). In hepatocytes, DAB inhibited basal and glucagon-stimulated glycogenolysis with IC(50) values of 1.0+/-0.3 and 1.1+/-0.2 microM, respectively. The primary inhibitory effect of DAB on glycogenolysis was shown to be due to inhibition of glycogen phosphorylase but, at higher concentrations of DAB, inhibition of the debranching enzyme (4-alpha-glucanotransferase, EC 2.4.1.25) may have an effect. No effects on glycogen synthesis were observed, demonstrating that glycogen recycling does not occur in cultured hepatocytes under the conditions tested. Furthermore, DAB had no effects on phosphorylase kinase, the enzyme responsible for phosphorylation and thereby activation of glycogen phosphorylase, or on protein phosphatase 1, the enzyme responsible for inactivation of glycogen phosphorylase through dephosphorylation.

Citing Articles

Inhibition of mitochondrial fission activates glycogen synthesis to support cell survival in colon cancer.

Hasani S, Young L, Van Nort W, Banerjee M, Rivas D, Kim J Cell Death Dis. 2023; 14(10):664.

PMID: 37816729 PMC: 10564897. DOI: 10.1038/s41419-023-06202-3.

Dual treatment with a fixed ratio of glucagon and insulin increases the therapeutic window of insulin in diabetic rats.

Pedersen C, Bouman S, Porsgaard T, Rosenkilde M, Roed N Physiol Rep. 2018; 6(6):e13657.

PMID: 29595915 PMC: 5875541. DOI: 10.14814/phy2.13657.

Natural products, an important resource for discovery of multitarget drugs and functional food for regulation of hepatic glucose metabolism.

Li J, Yu H, Wang S, Wang W, Chen Q, Ma Y Drug Des Devel Ther. 2018; 12:121-135.

PMID: 29391777 PMC: 5768189. DOI: 10.2147/DDDT.S151860.

Oligodendrocyte Progenitor Cells Directly Utilize Lactate for Promoting Cell Cycling and Differentiation.

Ichihara Y, Doi T, Ryu Y, Nagao M, Sawada Y, Ogata T J Cell Physiol. 2016; 232(5):986-995.

PMID: 27861886 PMC: 5299506. DOI: 10.1002/jcp.25690.

Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy.

Zois C, Harris A J Mol Med (Berl). 2016; 94(2):137-54.

PMID: 26882899 PMC: 4762924. DOI: 10.1007/s00109-015-1377-9.

References

Bollen M, Vandebroeck A, Stalmans W . 1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase a. Biochem Pharmacol. 1988; 37(5):905-9. DOI: 10.1016/0006-2952(88)90179-7. View

Diraison F, Large V, Brunengraber H, Beylot M . Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis and hepatic fatty acid oxidation in NIDDM. Diabetologia. 1998; 41(2):212-20. DOI: 10.1007/s001250050892. View

Bollen M, Stalmans W . The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the alpha-1,6-glucosidase activity of the debranching enzyme. Eur J Biochem. 1989; 181(3):775-80. DOI: 10.1111/j.1432-1033.1989.tb14792.x. View

Martin J, Veluraja K, Ross K, Johnson L, Fleet G, Ramsden N . Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. Biochemistry. 1991; 30(42):10101-16. DOI: 10.1021/bi00106a006. View

Nyomba B, Brautigan D, Schlender K, Wang W, Bogardus C, Mott D . Deficiency in phosphorylase phosphatase activity despite elevated protein phosphatase type-1 catalytic subunit in skeletal muscle from insulin-resistant subjects. J Clin Invest. 1991; 88(5):1540-5. PMC: 295665. DOI: 10.1172/JCI115464. View

Rothman D, Magnusson I, Katz L, Shulman R, Shulman G . Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science. 1991; 254(5031):573-6. DOI: 10.1126/science.1948033. View

DeFronzo R, Bonadonna R, Ferrannini E . Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992; 15(3):318-68. DOI: 10.2337/diacare.15.3.318. View

Bollen M, Stalmans W . The structure, role, and regulation of type 1 protein phosphatases. Crit Rev Biochem Mol Biol. 1992; 27(3):227-81. DOI: 10.3109/10409239209082564. View

Barrett E, Liu Z . Hepatic glucose metabolism and insulin resistance in NIDDM and obesity. Baillieres Clin Endocrinol Metab. 1993; 7(4):875-901. DOI: 10.1016/s0950-351x(05)80238-1. View

10.

Grunnet N, Jensen S, Dich J . Absence of glycogen cycling in cultured rat hepatocytes. Arch Biochem Biophys. 1994; 309(1):18-23. DOI: 10.1006/abbi.1994.1077. View

11.

Watson K, Mitchell E, Johnson L, Son J, Bichard C, Orchard M . Design of inhibitors of glycogen phosphorylase: a study of alpha- and beta-C-glucosides and 1-thio-beta-D-glucose compounds. Biochemistry. 1994; 33(19):5745-58. DOI: 10.1021/bi00185a011. View

12.

Pimenta W, Nurjhan N, Jansson P, Stumvoll M, Gerich J, Korytkowski M . Glycogen: its mode of formation and contribution to hepatic glucose output in postabsorptive humans. Diabetologia. 1994; 37(7):697-702. DOI: 10.1007/BF00417694. View

13.

Asano N, Oseki K, Kizu H, Matsui K . Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994; 37(22):3701-6. DOI: 10.1021/jm00048a006. View

14.

Magnusson I, Rothman D, Gerard D, Katz L, Shulman G . Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes. 1995; 44(2):185-9. DOI: 10.2337/diab.44.2.185. View

15.

Asano N, Kizu H, Oseki K, Tomioka E, Matsui K, Okamoto M . N-alkylated nitrogen-in-the-ring sugars: conformational basis of inhibition of glycosidases and HIV-1 replication. J Med Chem. 1995; 38(13):2349-56. DOI: 10.1021/jm00013a012. View

16.

Massillon D, Bollen M, DE WULF H, Overloop K, Vanstapel F, Van Hecke P . Demonstration of a glycogen/glucose 1-phosphate cycle in hepatocytes from fasted rats. Selective inactivation of phosphorylase by 2-deoxy-2-fluoro-alpha-D-glucopyranosyl fluoride. J Biol Chem. 1995; 270(33):19351-6. DOI: 10.1074/jbc.270.33.19351. View

17.

SUTHERLAND E, Robison G . The role of cyclic AMP in the control of carbohydrate metabolism. Diabetes. 1969; 18(12):797-819. DOI: 10.2337/diab.18.12.797. View

18.

Stalmans W, Laloux M, HERS H . The interaction of liver phosphorylase a with glucose and AMP. Eur J Biochem. 1974; 49(2):415-27. DOI: 10.1111/j.1432-1033.1974.tb03847.x. View

19.

Seglen P . Preparation of isolated rat liver cells. Methods Cell Biol. 1976; 13:29-83. DOI: 10.1016/s0091-679x(08)61797-5. View

20.

Feliu J, Hue L, HERS H . Hormonal control of pyruvate kinase activity and of gluconeogenesis in isolated hepatocytes. Proc Natl Acad Sci U S A. 1976; 73(8):2762-6. PMC: 430732. DOI: 10.1073/pnas.73.8.2762. View